<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04224116</url>
  </required_header>
  <id_info>
    <org_study_id>TA</org_study_id>
    <nct_id>NCT04224116</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid Contribution in the Prevention of Perioperative Bleeding in Thoracic Surgery</brief_title>
  <acronym>Bleeding</acronym>
  <official_title>Tranexamic Acid Contribution in the Prevention of Perioperative Bleeding in Pulmonary Resection Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Tunis El Manar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Tunis El Manar</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bleeding after thoracic surgery is a major cause of perioperative hemodynamic instability and
      transfusion requirement, which can lead to a rise of morbidity, mortality and costs.

      The objective of this study is to evaluate the efficiency of tranexamic acid (TA) in the
      prevention of perioperative bleeding in thoracic hemorrhagic surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It's a randomized, double-blind, prospective study including patients over the age of 18
      years old, programmed for potentially hemorrhagic thoracic surgery, such as pulmonary
      resection for aspergilloma, pulmonary tuberculosis, pleural decortication, lobectomy with
      parietectomy or redux. Demographic, clinical, biological data as well as transfusion
      requirements, blood loss and perioperative complications were identified.

      Two groups of patients:

        -  TA group: receiving tranexamic acid (25mg/kg) in bolus at induction followed by 2mg/kg/h
           in continuous infusion until the end of the act.

        -  Serum saline isotonic (SSI) group: placebo with isotonic saline serum.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2014</start_date>
  <completion_date type="Actual">October 2, 2019</completion_date>
  <primary_completion_date type="Actual">October 2, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>It's a randomized, double-blind, prospective study including patients over the age of 18 years old, programmed for potentially hemorrhagic thoracic surgery, such as pulmonary resection for aspergilloma, pulmonary tuberculosis, pleural decortication, lobectomy with parietectomy or redux. Demographic, clinical, biological data as well as transfusion requirements, blood loss and perioperative complications were identified.
Two groups of patients:
TA group: receiving tranexamic acid (25mg/kg) in bolus at induction followed by 2mg/kg/h in continuous infusion until the end of the act.
Serum saline isotonic (SSI) group: placebo with isotonic saline serum.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>double blind investigation</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>intraoperative bleeding volume</measure>
    <time_frame>five hours</time_frame>
    <description>The blood volume collected in the suction tanks and the operative drapes intraoperatively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of red globular caps transfused for each group</measure>
    <time_frame>one month</time_frame>
    <description>transfusion if hemoglobin less than 7 g / dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding volume in the thoracic drains postoperatively</measure>
    <time_frame>one month</time_frame>
    <description>bleeding volume in the thoracic drains postoperatively every day</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>Group TA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receiving tranexamic acid (25mg/kg) in bolus at induction followed by 2mg/kg/h in continuous infusion until the end of the act.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group SSI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Serum saline isotonic (SSI) group: placebo with isotonic saline serum.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid injection</intervention_name>
    <description>to receive tranexamic acid (25mg/kg) in bolus at induction followed by 2mg/kg/h in continuous infusion until the end of the act.</description>
    <arm_group_label>Group TA</arm_group_label>
    <other_name>EXACYL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SSI</intervention_name>
    <description>Serum Salin isotonic injected</description>
    <arm_group_label>Group SSI</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  over the age of 18 years old, programmed for potentially hemorrhagic thoracic surgery,
             such as pulmonary resection for aspergilloma, pulmonary tuberculosis, pleural
             decortication, lobectomy with parietectomy or redux.

        Exclusion Criteria:

          -  Patients who have had a major complication of surgery other than bleeding requiring
             revision within 24 hours or a complication related to anesthesia, and cases of
             non-compliance with the anesthetic protocol are excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tahar Mestiri, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>university Manar Tunis</affiliation>
  </overall_official>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>January 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Tunis El Manar</investigator_affiliation>
    <investigator_full_name>Amani Ben Haj Youssef</investigator_full_name>
    <investigator_title>Tranexamic Acid Contribution in the Prevention of Perioperative Bleeding in Pulmonary Resection Surgery</investigator_title>
  </responsible_party>
  <keyword>tranexamic acid</keyword>
  <keyword>Antifibrinolytic agents</keyword>
  <keyword>bleeding</keyword>
  <keyword>blood transfusion</keyword>
  <keyword>thoracic surgery.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

